Connection
Samer Al Hadidi to Clinical Trials as Topic
This is a "connection" page, showing publications Samer Al Hadidi has written about Clinical Trials as Topic.
|
|
Connection Strength |
|
 |
|
 |
|
2.481 |
|
|
|
-
Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
Score: 0.678
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
Score: 0.662
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
Score: 0.586
-
Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. Eur J Cancer. 2024 May; 203:114045.
Score: 0.191
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
Score: 0.162
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
Score: 0.153
-
Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. Oncologist. 2025 Feb 06; 30(2).
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|